Zynex将Q4 2024收入指导修订为0.09 EPS、53.6M收入和0.20Final 2024 EPS。 Zynex revises Q4 2024 earnings guidance to $0.09 EPS, $53.6M revenue, and $0.20 FY 2024 EPS.

医疗器械公司Zynex已修订其2024年第四季度的利预测,每股收益为0.09美元,收入至少为5360万美元,略低于分析师的预期. Zynex, a medical device company, has revised its Q4 2024 earnings guidance to an EPS of $0.09 and revenue of at least $53.6 million, slightly below analyst expectations. 2024财政年度EPS指南更新为0.20。 The FY 2024 EPS guidance is updated to $0.20. 最近,导演Joshua R. Disbrow购买了7 000股股票,52.13%的股票由内部人持有。 Recently, Director Joshua R. Disbrow bought 7,000 shares, while 52.13% of the stock is held by insiders. Zynex专门从事通过电动刺激进行疼痛管理和肌肉活化的装置。 Zynex specializes in devices for pain management and muscle activation through electrical stimulation.